Press release
Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market
The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine.These twin forces, rising demand fueled by aging and disease prevalence along with technological innovation, are propelling unprecedented growth across biopharma markets. The global biotechnology sector is projected to expand from $1.74 trillion in 2025 to over $5 trillion by 2034, representing a CAGR of 12.5 percent. Specialty pharmaceuticals, including biologics and novel drug delivery systems, are expected to grow even faster, with forecasts predicting a 26.5 percent CAGR over the same period.
Oncology remains a key driver, with spending on cancer medicines forecasted to nearly double from $252 billion in 2024 to $441 billion by 2029. Meanwhile, veterinary oncology is emerging as a high-potential frontier, with the U.S. market alone projected to reach $1.48 billion by 2030, driven by rising pet ownership and demand for advanced care. The urology therapeutics segment also shows steady growth potential, expected to rise from $10.5 billion in 2024 to $15.8 billion by 2033.
Amid this expansive and interconnected landscape, Medicus Pharma Ltd. (NASDAQ: MDCX) is methodically positioning itself to capitalize on these powerful market tailwinds. Through a diversified portfolio of innovative drug delivery platforms and targeted therapies, Medicus addresses some of the most pressing health challenges across human and veterinary medicine.
Medicus Pharma: Methodically Building a High-Leverage Growth Story
Though still flying under many investors' radars, Medicus Pharma is rapidly assembling the elements of a high-leverage growth story. On June 2, the company completed a $7 million public offering, selling 2,260,000 units at $3.10 each. Each unit includes one common share plus one warrant exercisable at the same price over five years.
The capital will primarily fund a Phase 2 proof-of-concept trial in basal cell carcinoma (BCC) using Medicus's flagship doxorubicin-loaded dissolvable microneedle patch (D-MNA). Additional funds may support broader development in non-melanoma skin cancers or other pipeline programs.
Strategic Veterinary Expansion: FDA Submission for Equine Squamous Cell Carcinoma
This timely financing was quickly followed by a major regulatory milestone. On June 9, Medicus announced submission of a formal product development plan to the U.S. FDA for a veterinary application of D-MNA targeting equine squamous cell carcinoma (SCC).
The program is advancing under an Investigational New Animal Drug (INAD) file, aiming for conditional approval. It leverages the same microneedle patch technology used in human dermatologic trials, demonstrating a strategic effort to repurpose clinical data and technology across human and veterinary markets.
An Untapped Veterinary Oncology Opportunity
The equine indication represents a significant market opportunity. As CEO Dr. Raza Bokhari highlighted, "In veterinary medicine, where only a handful of oncology drugs are approved, developing a non-invasive treatment for equine SCC targets a largely unmet need, a potential $250 million market."
The planned study will enroll 50 horses across five U.S. sites in a placebo-controlled design, comparing two D-MNA doses against placebo, with tumor response assessed at day 90. Medicus has secured FDA Minor Use in Major Species (MUMS) Designation, which grants seven years of market exclusivity upon approval, a valuable commercial advantage in a segment with limited competition.
D-MNA Platform: Promising Safety and Efficacy Data
The D-MNA patch, originally developed for human skin cancers, is supported by encouraging early data. A Phase 1 trial in Australia (SKNJCT-001) involving 13 patients with nodular BCC showed the treatment was well tolerated with no dose-limiting toxicities. Remarkably, 46 percent of lesions achieved complete histological clearance after a single application, an impressive result given the minimally invasive delivery.
This platform delivers doxorubicin directly into the dermis through a biodegradable microneedle array, minimizing systemic exposure while concentrating the drug's effect at the tumor site.
Expanding Clinical Trials Across Continents
Building on this foundation, Medicus is running two Phase 2 trials. In the U.S., the SKNJCT-003 study recently expanded enrollment from 60 to 90 patients following a positive interim analysis that showed over 60 percent clinical clearance. This multicenter, placebo-controlled trial compares the patch to the standard of care, with European sites now joining due to growing investigator interest.
Concurrently, the SKNJCT-004 trial in the United Arab Emirates involves 36 patients across four hospitals, including Cleveland Clinic Abu Dhabi, targeting both histological and clinical clearance endpoints.
Strategic Acquisition: Entering Late-Stage Urology
Complementing its internal pipeline, Medicus is also positioning itself as a consolidator of high-value assets. In April, the company signed a binding letter of intent to acquire UK-based Antev Ltd., whose lead candidate, Teverelix, is a GnRH antagonist in late-stage development for two urology indications: acute urinary retention (AUR) due to benign prostatic hyperplasia and hormone-sensitive prostate cancer in patients at elevated cardiovascular risk.
These combined markets represent a $6 billion annual opportunity, and Teverelix has completed multiple clinical trials in Europe. Under the deal, Antev shareholders would receive approximately 19 percent of Medicus's post-merger equity, plus up to $65 million in milestone payments tied to regulatory and commercial successes.
A Platform With Multiple Growth Levers
Together, Medicus offers optionality and platform leverage across human oncology, veterinary medicine, and dermatology, all fields marked by limited innovation and strong pricing power.
Its lead asset is already in Phase 2 with international trial sites and active FDA engagement. The veterinary program offers a faster commercialization path with fewer regulatory barriers, while the Antev acquisition could propel Medicus into late-stage, multi-billion-dollar indications.
Why Investors Should Watch MDCX
Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory filing. Clinical trials across humans and animals are expanding, and a transformative acquisition is imminent.
With a methodical approach tying together clinical progress, intellectual property, and market strategy, Medicus is quietly building momentum, making MDCX a stock to watch closely in the second half of 2025.
Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=medicus-pharma-ltd-nasdaq-mdcx-positioned-for-growth-in-a-5-trillion-biotech-market]
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market here
News-ID: 4059258 • Views: …
More Releases from ABNewswire

Keratoconus Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Keratoconus pipeline constitutes 3+ key companies continuously working towards developing 3+ Keratoconus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Keratoconus Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Keratoconus Market.
The Keratoconus Pipeline report embraces in-depth commercial and clinical…

Medicus Pharma Ltd. (NASDAQ: MDCX) Builds Momentum With Antev Acquisition and Pi …
In the biotech sector, meaningful news often serves as the spark that brings smaller companies into sharper investor focus. Clinical readouts, regulatory decisions, and strategic acquisitions can materially shift the outlook for a business that may have otherwise flown under the radar. These developments not only shape the future of a company's pipeline but can also reframe its value proposition in the eyes of the market. For investors, recognizing when…

Connecticut Waterproofing Services Leader Marks Nearly Five Decades of Reliable …
Eastern Waterproofing Co. Inc celebrates nearly 48 years of family-operated service in Connecticut, specializing in moisture control and basement dehumidification solutions for South Windsor, Hartford, and surrounding communities.
Eastern Waterproofing Co. Inc continues to set industry standards after nearly 48 years of providing dependable waterproofing services [https://maps.app.goo.gl/EhJ6zW2hAXsGnFdp9] throughout Connecticut. The South Windsor-based company has maintained its family-operated foundation since 1976, establishing itself as a trusted resource for homeowners and businesses facing…

Minuteman Press Reports Significant Growth in Traditional Printing Demand Amid D …
Minuteman Press reports 40% growth in traditional printing demand as businesses shift toward tangible marketing strategies, with local franchises adapting services to meet evolving customer needs nationwide.
The printing industry is experiencing a notable renaissance, with Minuteman Press [http://minuteman.com/] franchise locations nationwide reporting a 40% increase in demand for tangible marketing materials over the past 18 months. This market shift reflects a growing recognition among businesses that physical marketing materials create…
More Releases for Medicus
Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend …
The crucial role of vaccines in protecting public health couldn't have been clearer than with the recent coronavirus pandemic. COVID-19 vaccines were instrumental in helping to reduce the spread of the virus, propelling vaccines to the top ten therapy category by sales as of 2023.
At the height of the pandemic, Cominarty, which was jointly developed by Pfizer and BioNTech, emerged as the leading covid vaccine, recording peak sales of about…
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To …
Now that the SPDR S&P Biotech index is displaying signs of renewed strength, the biotech boom could resume. In the past three months alone, the index has soared by 23% due to a number of factors, such as an increase in high-profile acquisitions and President Trump's decisions to delay tariffs for drug imports. With the biotech market poised to grow from $1.74 trillion in 2025 to $5.04 trillion by 2034,…
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Coul …
Skin cancer is the most common form of cancer in the United States, with more than 9,500 cases getting diagnosed every day. In fact, more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined.
The most common form of skin cancer is basal cell carcinoma (BCC), which accounts for over 5 million cases of all skin cancers diagnosed in the U.S. each year. Currently,…
Pediatric Tourniquet Market Scope By Players - Safeguard Medical, DarMar, Medicu …
MarketsandResearch.biz has newly added a research report titled Pediatric Tourniquet Market 2023 is a detailed and dedicated analysis of the present scenario of the market covering the various aspects applicable to business growth. The report evaluates the market, putting forth all-inclusive data that enriches the scope, understanding, and application of this report. The report encompasses the information on the global Pediatric Tourniquet market's status. It presents a detailed analysis of…
X-Ray Cassette Holders market: High-growth Segments and their Share Forecasts | …
"The global X-Ray Cassette Holders Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global X-Ray Cassette Holders Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of…
Glucose Meters Market Report- Demands, Size, Top Key Players, Industry Analysis …
The research reports on Glucose Meters Market report gives detailed overview of factors that affect global business scope. Glucose Meters Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Glucose Meters Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.
Get FREE…